Chang, A., Sherman, S. K., Howe, J. R., & Sahai, V. (2022). Progress in the management of pancreatic neuroendocrine tumors. Annual Review of Medicine, 73, 213–229. https://doi.org/10.1146/annurev-med-042320-011248

Article  PubMed  CAS  Google Scholar 

Rindi, G., Mete, O., Uccella, S., Basturk, O., La Rosa, S., Brosens, L. A. A., Ezzat, S., de Herder, W. W., Klimstra, D. S., Papotti, M., & Asa, S. L. (2022). Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocrine Pathology, 33(1), 115–154. https://doi.org/10.1007/s12022-022-09708-2

Article  PubMed  CAS  Google Scholar 

Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017). Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncology, 3(10), 1335–1342. https://doi.org/10.1001/jamaoncol.2017.0589

Article  PubMed  PubMed Central  Google Scholar 

Frilling, A., & Clift, A. K. (2015). Therapeutic strategies for neuroendocrine liver metastases. Cancer, 121(8), 1172–1186. https://doi.org/10.1002/cncr.28760

Article  PubMed  CAS  Google Scholar 

Chang, J. Y., Ruff, S. M., & Cloyd, J. M. (2024). Treatment strategies for borderline resectable pancreatic neuroendocrine tumors: A narrative review. Chinese Clinical Oncology, 13(2), Article 25. https://doi.org/10.21037/cco-23-145

Article  PubMed  Google Scholar 

Riihimaki, M., Hemminki, A., Sundquist, K., Sundquist, J., & Hemminki, K. (2016). The epidemiology of metastases in neuroendocrine tumors. International Journal of Cancer, 139(12), 2679–2686. https://doi.org/10.1002/ijc.30400

Article  PubMed  CAS  Google Scholar 

Sonbol, M. B., Mazza, G. L., Mi, L., Oliver, T., Starr, J., Gudmundsdottir, H., Cleary, S. P., Hobday, T., & Halfdanarson, T. R. (2022). Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: A SEER database analysis. The oncologist, 27(7), 573–578. https://doi.org/10.1093/oncolo/oyac049

Article  PubMed  PubMed Central  Google Scholar 

Fan, J. H., Zhang, Y. Q., Shi, S. S., Chen, Y. J., Yuan, X. H., Jiang, L. M., Wang, S. M., Ma, L., He, Y. T., Feng, C. Y., Sun, X. B., Liu, Q., Deloso, K., Chi, Y., & Qiao, Y. L. (2017). A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in China. Oncotarget, 8(42), 71699–71708. https://doi.org/10.18632/oncotarget.17599

Article  PubMed  PubMed Central  Google Scholar 

Li, J., Huang, L., Liao, C., Liu, G., Tian, Y., & Chen, S. (2023). Two machine learning-based nomogram to predict risk and prognostic factors for liver metastasis from pancreatic neuroendocrine tumors: A multicenter study. BMC Cancer, 23(1), 529. https://doi.org/10.1186/s12885-023-10893-4

Article  PubMed  PubMed Central  CAS  Google Scholar 

de Visser, K. E., & Joyce, J. A. (2023). The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 41(3), 374–403. https://doi.org/10.1016/j.ccell.2023.02.016

Article  PubMed  CAS  Google Scholar 

Tsilimigras, D. I., Brodt, P., Clavien, P. A., Muschel, R. J., D’Angelica, M. I., Endo, I., Parks, R. W., Doyle, M., de Santibanes, E., & Pawlik, T. M. (2021). Liver metastases. Nature Reviews Disease Primers, 7(1), Article 27. https://doi.org/10.1038/s41572-021-00261-6

Article  PubMed  Google Scholar 

Chauhan, A., Chan, K., Halfdanarson, T. R., Bellizzi, A. M., Rindi, G., O’Toole, D., Ge, P. S., Jain, D., Dasari, A., Anaya, D. A., Bergsland, E., Mittra, E., Wei, A. C., Hope, T. A., Kendi, A. T., Thomas, S. M., Flem, S., Brierley, J., Asare, E. A., … Shi, C. (2024). Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA: A Cancer Journal for Clinicians, 74(4), 359–367. https://doi.org/10.3322/caac.21840

Article  PubMed  Google Scholar 

Zhang, X. F., Xue, F., Wu, Z., Lopez-Aguiar, A. G., Poultsides, G., Makris, E., Rocha, F., Kanji, Z., Weber, S., Fisher, A., Fields, R., Krasnick, B. A., Idrees, K., Smith, P. M., Cho, C., Beems, M., Lyu, Y., Maithel, S. K., & Pawlik, T. M. (2022). Development and validation of a modified eighth AJCC staging system for primary pancreatic neuroendocrine tumors. Annals of Surgery, 275(6), e773–e780. https://doi.org/10.1097/SLA.0000000000004039

Article  PubMed  Google Scholar 

Singhi, A. D., Liu, T. C., Roncaioli, J. L., Cao, D., Zeh, H. J., Zureikat, A. H., Tsung, A., Marsh, J. W., Lee, K. K., Hogg, M. E., Bahary, N., Brand, R. E., McGrath, K. M., Slivka, A., Cressman, K. L., Fuhrer, K., & O’Sullivan, R. J. (2017). Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clinical Cancer Research, 23(2), 600–609. https://doi.org/10.1158/1078-0432.CCR-16-1113

Article  PubMed  CAS  Google Scholar 

Cejas, P., Drier, Y., Dreijerink, K. M. A., Brosens, L. A. A., Deshpande, V., Epstein, C. B., Conemans, E. B., Morsink, F. H. M., Graham, M. K., Valk, G. D., Vriens, M. R., Castillo, C. F., Ferrone, C. R., Adar, T., Bowden, M., Whitton, H. J., Da Silva, A., Font-Tello, A., Long, H. W., … Shivdasani, R. A. (2019). Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nature Medicine, 25(8), 1260–1265. https://doi.org/10.1038/s41591-019-0493-4

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hackeng, W. M., Brosens, L. A. A., Kim, J. Y., O’Sullivan, R., Sung, Y. N., Liu, T. C., Cao, D., Heayn, M., Brosnan-Cashman, J., An, S., Morsink, F. H. M., Heidsma, C. M., Valk, G. D., Vriens, M. R., van Nieveen Dijkum, E., Offerhaus, G. J. A., Dreijerink, K. M. A., Zeh, H., Zureikat, A. H., … Singhi, A. D. (2022). Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut, 71(5), 961–973. https://doi.org/10.1136/gutjnl-2020-322595

Article  PubMed  CAS  Google Scholar 

Reidy-Lagunes, D., Pandit-Taskar, N., O’Donoghue, J. A., Krebs, S., Staton, K. D., Lyashchenko, S. K., Lewis, J. S., Raj, N., Gonen, M., Lohrmann, C., Bodei, L., & Weber, W. A. (2019). Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist (177)Lu-Satoreotide Tetraxetan. Clinical Cancer Research, 25(23), 6939–6947. https://doi.org/10.1158/1078-0432.CCR-19-1026

Article  PubMed  PubMed Central  Google Scholar 

Brunner, P., Jorg, A. C., Glatz, K., Bubendorf, L., Radojewski, P., Umlauft, M., Marincek, N., Spanjol, P. M., Krause, T., Dumont, R. A., Maecke, H. R., Muller-Brand, J., Briel, M., Schmitt, A., Perren, A., & Walter, M. A. (2017). The prognostic and predictive value of sstr(2)-immunohistochemistry and sstr(2)-targeted imaging in neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 44(3), 468–475. https://doi.org/10.1007/s00259-016-3486-2

Article  PubMed  CAS  Google Scholar 

Umetsu, S. E., Kakar, S., Basturk, O., Kim, G. E., Chatterjee, D., Wen, K. W., Hale, G., Shafizadeh, N., Cho, S. J., Whitman, J., Gill, R. M., Jones, K. D., Navale, P., Bergsland, E., Klimstra, D., & Joseph, N. M. (2023). Integrated genomic and clinicopathologic approach distinguishes pancreatic grade 3 neuroendocrine tumor from neuroendocrine carcinoma and identifies a subset with molecular overlap. Modern Pathology, 36(3), Article 100065. https://doi.org/10.1016/j.modpat.2022.100065

Article  PubMed  CAS  Google Scholar 

Lakis, V., Lawlor, R. T., Newell, F., Patch, A. M., Mafficini, A., Sadanandam, A., Koufariotis, L. T., Johnston, R. L., Leonard, C., Wood, S., Rusev, B., Corbo, V., Luchini, C., Cingarlini, S., Landoni, L., Salvia, R., Milella, M., Chang, D., Bailey, P., … Scarpa, A. (2021). DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 4(1), Article 155. https://doi.org/10.1038/s42003-020-01469-0

Article  PubMed  PubMed Central  CAS  Google Scholar 

Deschler-Baier, B., Krebs, M., Kroiss, M., Chatterjee, M., Gundel, D., Kestler, C., Kerscher, A., Kunzmann, V., Appenzeller, S., Maurus, K., Rosenwald, A., Bargou, R., Gerhard-Hartmann, E., & Venkataramani, V. (2024). Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch. NPJ Precision Oncology, 8(1), Article 167. https://doi.org/10.1038/s41698-024-00659-x

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li, A. Y., McCusker, M. G., Russo, A., Scilla, K. A., Gittens, A., Arensmeyer, K., Mehra, R., Adamo, V., & Rolfo, C. (2019). RET fusions in solid tumors. Cancer Treatment Reviews, 81, Article 101911. https://doi.org/10.1016/j.ctrv.2019.101911

Article  PubMed  CAS  Google Scholar 

Yamauchi, Y., Kodama, Y., Shiokawa, M., Kakiuchi, N., Marui, S., Kuwada, T., Sogabe, Y., Tomono, T., Mima, A., Morita, T., Matsumori, T., Ueda, T., Tsuda, M., Nishikawa, Y., Kuriyama, K., Sakuma, Y., Ota, Y., Maruno, T., Uza, N., … Seno, H. (2020). Rb and p53 execute distinct roles in the development of pancreatic neuroendocrine tumors. Cancer Research, 80(17), 3620–3630. https://doi.org/10.1158/0008-5472.CAN-19-2232

Article  PubMed  CAS  Google Scholar 

Joseph, N. M., Umetsu, S. E., Kim, G. E., Terry, M., Perry, A., Bergsland, E., & Kakar, S. (2024). Progression of low-grade neuroendocrine tumors (NET) to high-grade neoplasms harboring the NEC-like co-alteration of RB1 and TP53. Endocrine Pathology, 35(4), 325–337.